|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 100.79 USD | -0.84% |
|
-0.29% | -7.48% |
| 12:25pm | Bernstein Trims Price Target on Merck to $110 From $115 | MT |
| 11-29 | Astrazeneca's Enhertu, Orpathys Among 91 Drugs Added to China's National Reimbursement Drug List | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
| Capitalization | 257B 244B 227B 202B 360B 21,745B 395B 2,807B 1,045B 8,920B 966B 944B 38,696B | P/E ratio 2024 * |
14.3x | P/E ratio 2025 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise value | 280B 265B 247B 220B 392B 23,666B 430B 3,055B 1,138B 9,708B 1,051B 1,028B 42,113B | EV / Sales 2024 * |
4.37x | EV / Sales 2025 * | 3.94x |
| Free-Float |
70.72% | Yield 2024 * |
3% | Yield 2025 * | 3.14% |
More valuation ratios
* Estimated data
More news
Last Transcript: Merck & Co., Inc.
More recommendations
More press releases
More news
| 1 day | -0.69% | ||
| 1 week | -0.36% | ||
| Current month | -0.83% | ||
| 1 month | -1.06% | ||
| 3 months | -13.54% | ||
| 6 months | -21.51% | ||
| Current year | -7.54% |
1 week
99.70
103.45
1 month
94.48103.45
Current year
94.48134.63
1 year
94.48134.63
3 years
71.50134.63
5 years
65.25134.63
10 years
45.69134.63
| Director | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 2021-06-30 |
| Director of Finance/CFO | 55 | 2021-03-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 2020-07-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 64 | 2007-11-26 |
Patricia Russo
BRD | Director/Board Member | 71 | 1995-08-31 |
Robert Davis
CHM | Chairman | 57 | 2022-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.34% | 380 M€ | +10.03% | - | |
| 5.61% | 20 M€ | +15.66% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.73% | -0.36% | -4.06% | +36.41% | 257B | ||
| +0.69% | +6.22% | +36.93% | +223.53% | 716B | ||
| +2.44% | +3.65% | +11.62% | +120.15% | 474B | ||
| -0.25% | -0.70% | -2.64% | -1.53% | 373B | ||
| -1.17% | +2.01% | +25.30% | +54.54% | 323B | ||
| -0.08% | +0.83% | +3.78% | -29.67% | 233B | ||
| -0.31% | +1.07% | +7.86% | +25.89% | 211B | ||
| -0.37% | +0.94% | +2.98% | +28.44% | 209B | ||
| -1.66% | -5.38% | +2.07% | +38.28% | 152B | ||
| -1.43% | -1.24% | -11.73% | -51.27% | 149B | ||
| Average | -0.27% | +1.25% | +7.21% | +44.48% | 309.77B | |
| Weighted average by Cap. | +0.13% | +2.14% | +12.86% | +79.48% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 64.02B 60.68B 56.46B 50.39B 89.7B 5,415B 98.31B 699B 260B 2,221B 241B 235B 9,636B | 67.58B 64.05B 59.59B 53.19B 94.68B 5,716B 104B 738B 275B 2,345B 254B 248B 10,171B |
| Net income | 17.79B 16.86B 15.69B 14B 24.92B 1,504B 27.31B 194B 72.32B 617B 66.83B 65.34B 2,677B | 22.17B 21.01B 19.55B 17.45B 31.06B 1,875B 34.04B 242B 90.12B 769B 83.28B 81.43B 3,336B |
| Net Debt | 22.7B 21.52B 20.02B 17.87B 31.81B 1,920B 34.86B 248B 92.3B 788B 85.29B 83.39B 3,417B | 9.47B 8.98B 8.35B 7.46B 13.27B 801B 14.55B 103B 38.52B 329B 35.59B 34.8B 1,426B |
More financial data
* Estimated data
Employees
71,000
Sector
Pharmaceuticals
Calendar
2024-12-03
- Evercore ISI HealthCONx Conference
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-02 | 100.90 $ | -0.73% | 2,029,556 |
| 24-11-29 | 101.64 $ | -1.44% | 6,081,177 |
| 24-11-27 | 103.12 $ | +1.48% | 9,802,172 |
| 24-11-26 | 101.62 $ | +0.45% | 9,324,084 |
| 24-11-25 | 101.16 $ | +2.00% | 34,659,091 |
Delayed Quote Nyse, December 02, 2024 at 10:47 am
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
101.64USD
Average target price
130.33USD
Spread / Average Target
+28.22%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRK Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition